CSL:ASX

CSL shares are trading at AUD 144, well below the 20‑day (≈148.7), 50‑day (≈165.2) and 200‑day (≈204.3) moving averages, indicating a bearish price momentum. The 14‑day RSI of 32.7 suggests the stock is oversold, while the MACD histogram has turned positive (≈0.36) and the signal line is now bullish, hinting at a possible short‑term rebound toward the support level of AUD 140.9. Volatility remains elevated at roughly 35% over the past 30 days, but the beta of 0.39 points to lower systematic risk compared with the broader market. On the fundamentals side, CSL’s dividend yield of 3.02% and a payout ratio near 45% are supported by solid operating cash flow (AUD 3.6 bn) and a robust free cash flow generation (AUD 1.85 bn). However, the latest half‑year results showed an 81% plunge in net profit as the company undergoes a strategic transformation, and the DCF‑derived fair value of AUD 32 is far below the current price, creating a stark valuation discrepancy.
The company’s long‑term outlook is buoyed by a $1.5 bn expansion of its Illinois plasma‑therapy manufacturing site, signaling commitment to capacity growth in a high‑margin segment. Analysts forecast a target median price of AUD 201.5, implying upside potential of over 40% from today’s level, and the consensus recommendation remains a “Buy”. While sector‑specific regulatory and clinical trial risks remain medium to high, CSL’s diversified geographic footprint and strong balance sheet mitigate many of these concerns, making the stock attractive for investors seeking a blend of growth and income.